Understand the source comparison
Best Peptides for Hemorrhoids: Mechanism Comparison
BPC-157 VEGF receptor upregulation, NO synthesis, FAK-paxillin pathway activation 10–20mcg/kg daily (animal models) Subcutaneous injection Rodent studies, one small human case series Strong mechanistic rationale; human clinical data lacking Thymosin Beta-4 Act
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF receptor upregulation, NO synthesis, FAK-paxillin pathway activation
- 10–20mcg/kg daily (animal models)
- Subcutaneous injection
- Rodent studies, one small human case series
- Strong mechanistic rationale; human clinical data lacking
- Thymosin Beta-4
- Actin sequestering, CXCR4/SDF-1 modulation, NF-κB pathway suppression
- 2–4mg twice weekly
- Phase II trials in wound healing (non-anorectal)
- Established wound healing peptide; no hemorrhoid-specific trials
- KPV (Lys-Pro-Val)
- Anti-inflammatory tripeptide, MSH-receptor agonist
- 500mcg–2mg daily
- Topical or subcutaneous
- Preclinical only
- Promising for IBD-related inflammation; minimal hemorrhoid research
- GHK-Cu
- Copper-binding peptide, TGF-β activation, metalloproteinase modulation
- 1–3mg daily
- Topical application
- Dermal wound studies
- Collagen synthesis support; unclear relevance to vascular tissue
- KPV 5MG deserves mention for its anti-inflammatory profile. It's an α-MSH (melanocyte-stimulating hormone) fragment that reduces inflammatory cytokine release. Rodent studies in ulcerative colitis show significant reduction in mucosal inflammation with oral or rectal KPV administration. The mechanism is relevant to hemorrhoidal inflammation, but clinical translation hasn't occurred.